Wirksamkeit von Phytotherapeutika in der psychiatrischen Behandlung

Zusammenfassung

Hintergrund: Der Einsatz von Phytotherapeutika hat in den letzten Jahren auch in der Behandlung psychiatrischer Erkrankungen erheblich an Bedeutung gewonnen.

Methodik: Dieser narrative Überblick fasst die bisherige Evidenzlage zu Wirkungen und Nebenwirkungen pflanzlicher Arzneimittel bei der Behandlung von depressiven Störungen, Angstzuständen, Schlafstörungen und Hyperaktivitäts- und Aufmerksamkeitsstörungen auf Basis von Metaanalysen und systematischen Übersichtsarbeiten zusammen.

Ergebnisse: Bei der Behandlung von leichten bis mittelschweren depressiven Episoden ist Johanniskraut evidenzbasiert und gut verträglich. Wechselwirkungen mit anderen Medikamenten sollten unbedingt beachtet werden. Für andere Phytotherapeutika ist die Datenlage bisher weniger ausreichend, um konkrete Aussagen treffen zu können.

Schlussfolgerungen: Phytotherapeutika stellen in der Behandlung psychiatrischer Erkrankungen möglicherweise eine gute Alternative oder Ergänzung zu konventionellen Psychopharmaka dar. Sie sind im Vergleich oft nebenwirkungsärmer, gut verträglich und haben eine große therapeutische Breite. Weitere randomisiert kontrollierte Studien sind allerdings dringend indiziert.

Abstract

The effectiveness of herbal remedies in the treatment of psychiatric disorders: a narrative overview of current research

Background: The use of herbal remedies in the treatment of psychiatric disorders has gained increasing importance in recent years.

Method: This narrative overview summarizes current evidence from meta-analyses and systematic reviews on the effects and side effects of herbal remedies in the treatment of depression, anxiety, sleep disorders and hyperactivity and attention deficit disorders.

Results: In the treatment of mild to moderately severe depressive episodes, St. John’s wort is evidence-based and well tolerated. Interactions with other drugs should be considered. For other phytotherapeutic drugs, evidence is limited.

Conclusion: In the treatment of psychiatric disorders, phytotherapeutic drugs may present a good alternative or supplement to conventional psychotherapeutic drugs. In comparison, they show few side effects, are well tolerated and have a wide therapeutic range. Further randomized controlled studies are therefore warranted.

Schlüsselwörter

Phytotherapie - Phytopharmaka - Psychiatrie

Key words

herbal medicine - psychiatry - phytotherapeutic agents

Publikationsverlauf

Artikel online veröffentlicht:
03. Dezember 2020

• Literatur

• 1 Adib-Hajbaghery M, Mousavi SN. The effects of chamomile extract on sleep quality among elderly people: A clinical trial. Complement Ther Med 2017; 35: 109-114.
• 2 Anheyer D, Lauche R, Schumann D. et al. Herbal medicines in children with attention deficit hyperactivity disorder (ADHD): A systematic review. Complement Ther Med 2017; 30: 14-23.
• 3 Apaydin EA, Maher AR, Shanman R. et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev 2016; 5: 148.
• 4 Baek JH, Nierenberg AA, Kinrys G. Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. Aust N Z J Psychiatry 2014; 48: 705-715.
• 5 Baric H, Dordevic V, Cerovecki I. et al. Complementary and alternative medicine treatments for generalized anxiety disorder: Systematic review and meta-analysis of randomized controlled trials. Adv Ther 2018; 35: 261-288.
• 6 Bent S, Padula A, Moore D. et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006; 119: 1005-1012.
• 7 Bündnis Phytotherapie. Positionspapier - Förderung der Phytotherapie in Deutschland [Abrufdatum: 23.04.2018].. http://www.buendnis-phytotherapie.de/images/Buendnis%20Phytotherapie_PP_Foerderung_Phytotherapie_final.pdf
• 8 Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than St. John’s Wort, in the treatment of depression: a systematic review. Altern Med Rev. 2011. ; 16: 40-49
• 9 European Medicines Agency. . Herbal medicinal products. [Abrufdatum: 19.04.2018]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000208.jsp
• 10 Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L. et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11: 505-511.
• 11 Hausenblas HA, Saha D, Dubyak PJ. et al. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med 2013; 11: 377-383.
• 12 Hoyer J, Köllner V. Pflanzliche Mittel bei Angststörungen. PiD Psychotherapie im Dialog 2015; 16: 56-59.
• 13 Italia S, Brand H, Heinrich J. et al. Utilization of complementary and alternative medicine (CAM) among children from a German birth cohort (GINIplus): patterns, costs, and trends of use. BMC Complement Altern Med 2015; 15: 49. doi:10.1186/s12906-015-0569-8
• 14 Kasper S, Gastpar M, Müller W. et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder - A randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 2014; 17: 859-869
• 15 Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med 2016; 29: 56-62
• 16 Kongkeaw C, Dilokthornsakul P, Thanarangsarit P. et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol 2014; 151: 528-535
• 17 Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev 2015; 24: 1-12. doi:10.1016/j.smrv.2014.12.003
• 18 Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev 2008; (04) : CD000448.
• 19 Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron / curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J Affect Disord 2017; 207: 188-196.
• 20 Möller HJ, Volz HP, Dienel A. et al. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2019; 269: 183-193.
• 21 Nematolahi P, Mehrabani M, Karami-Mohajeri S. et al. Effects of Rosmarinus officinalis L. on memory performance, anxiety, depression, and sleep quality in university students: A randomized clinical trial. Complement Ther Clin Pract 2018; 30: 24-28.
• 22 Ng QX, Koh SSH, Chan HW. et al. Clinical use of curcumin in depression: A meta-analysis. J Am Med Dir Assoc 2017; 18: 503-508.
• 23 Schnabel K, Binting S, Witt CM. et al. Use of complementary and alternative medicine by older adults – a cross-sectional survey. BMC Geriatrics 2014; 14: 38
• 24 Tan MS, Yu JT, Tan CC. et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimer’s Dis 2015; 43: 589-603.
• 25 Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 2010; 17: 94-99.
• 26 Zick SM, Wright BD, Sen A. et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med 2011; 11: 78.